Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection
March 24, 2022 09:00 ET
|
Revelation Biosciences, Inc.
-Primary endpoint analysis expected early Q2 2022- -Final data expected Q2 2022- SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or...
Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC
March 22, 2022 09:00 ET
|
Revelation Biosciences, Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of...
Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection
March 15, 2022 09:00 ET
|
Revelation Biosciences, Inc.
-Primary endpoint analysis expected early Q2 2022- -Final data expected Q2 2022- SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or...
Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
March 08, 2022 09:00 ET
|
Revelation Biosciences, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of...
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference
February 07, 2022 09:00 ET
|
Revelation Biosciences, Inc.
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of...
Revelation Biosciences Raises $7.76 Million in Equity Financing
January 24, 2022 08:00 ET
|
Revelation Biosciences, Inc.
SAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of...
Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection
January 20, 2022 09:00 ET
|
Revelation Biosciences, Inc.
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of...
Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis
January 18, 2022 09:00 ET
|
Revelation Biosciences, Inc.
SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of...
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
January 13, 2022 13:54 ET
|
Revelation Biosciences, Inc.
-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro anti-viral activity assay systems- -Previously...
Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
January 11, 2022 09:00 ET
|
Revelation Biosciences, Inc.
-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro anti-viral activity assay systems- -Previously...